Hunt­ing an ear­ly FDA OK, Igny­ta surges on promis­ing snap­shot of lung can­cer da­ta

Shares of Igny­ta $RXDX erupt­ed this morn­ing af­ter the biotech re­port­ed that its care­ful­ly cal­i­brat­ed ap­proach to non-small cell lung can­cer had paid off with some promis­ing pre­lim­i­nary da­ta.

Igny­ta and Loxo $LOXO have both dis­tin­guished them­selves by tak­ing a tu­mor-ag­nos­tic ap­proach to can­cer drug de­vel­op­ment, fo­cus­ing on a spe­cif­ic ge­net­ic mu­ta­tion that dri­ves can­cer. In the lat­est up­date, in­ves­ti­ga­tors for the com­pa­ny say that their drug en­trec­tinib — which tar­gets ROS1 fu­sion genes that dri­ve a thin slice of all NSCLC cas­es — achieved a 69% over­all re­sponse rate for lung can­cer con­firmed by in­de­pen­dent ob­servers. And the me­di­an pro­gres­sion-free sur­vival rate was 29.6 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER